Dr. Sepesi is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
499 E Hampden Ave
Ste 200
Englewood, CO 80113Phone+1 303-409-1430Fax+1 303-781-2218
Education & Training
University of Texas MD Anderson Cancer Center/University of Texas Medical School at HoustonFellowship, Thoracic Surgery, 2011 - 2013
University of RochesterResidency, Surgery, 2005 - 2011
University of ColoradoResidency, Internal Medicine, 2004 - 2004
Jagiellonian University Medical CollegeClass of 2004
Certifications & Licensure
FL State Medical License 2021 - Present
TX State Medical License 2013 - 2026
CO State Medical License 2023 - 2025
OK State Medical License 2020 - 2021
NY State Medical License 2008 - 2013- American Board of Surgery Surgery
- American Board of Thoracic Surgery Thoracic and Cardiac Surgery
Awards, Honors, & Recognition
- Fellow (FACS) American College of Surgeons
Clinical Trials
- Neoadjuvant Immune Checkpoint Blockade in Resectable Malignant Pleural Mesothelioma Start of enrollment: 2019 Oct 02
Roles: Principal Investigator, Contact
Publications & Presentations
PubMed
- Inflammation Mediated by Gut Microbiome Alterations Promotes Lung Cancer Development and an Immunosuppressed Tumor Microenvironment.Zahraa Rahal, Yuejiang Liu, Fuduan Peng, Sujuan Yang, Mohamed A Jamal
Cancer Immunology Research. 2024-12-03 - Impact of select actionable genomic alterations on efficacy of neoadjuvant immunotherapy in resectable non-small cell lung cancer.Nicolas Zhou, Cheuk H Leung, William N William Jr, Annikka Weissferdt, Apar Pataer
Journal for Immunotherapy of Cancer. 2024-10-23 - 3 citationsPerioperative and oncologic outcomes of pulmonary resection for synchronous oligometastatic non-small cell lung cancer: Evidence for surgery in advanced disease.Nathaniel Deboever, Kyle G Mitchell, Ahsan Farooqi, Ethan B Ludmir, Wayne L Hofstetter
The Journal of Thoracic and Cardiovascular Surgery. 2024-06-01
Authored Content
- My Top 5 Most Practice-Changing Presentations at WCLCOctober 2018
Press Mentions
Foundation Medicine Partners with Lung Cancer Research Foundation and the Lung Cancer Mutation Consortium on Screening Trial to Enable Precision TherapyJune 3rd, 2022- Circulating Cellular Determinants to Predict Response to Anti-PD-1 Monotherapy in Patients with Malignant Pleural MesotheliomaMay 15th, 2022
- Adding Atezolizumab to Neoadjuvant Cisplatin-Pemetrexed a Feasible Option in Malignant Pleural MesotheliomaOctober 15th, 2021
- Join now to see all
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
